Skip to content

From hypothesis to verifiable evidence.

Vemryx Life Sciences is a computational biomedical research lab. We use AI to read the literature, analyze public data and test hypotheses, with reproducible code and human review behind every conclusion.

The evidence ladder

Every project of ours states which step it is on. A hypothesis only moves up when the evidence supports it.

  1. Step 1: Registered hypothesisPilot project is here

    Question and hypothesis written down before any analysis.

  2. Step 2: Reproducible analysis

    Code, data and environment under version control.

  3. Step 3: Independent replication

    The finding holds in a second dataset.

  4. Step 4: Expert review

    A researcher in the field assesses methods and conclusions.

  5. Step 5: Experimental validation

    In the lab, with partner institutions.

  6. Step 6: Clinical trial

    With a sponsor, ethics approval and regulators.

  • Done in our computational lab
  • Only with partner institutions

What AI does here, and what it does not

Our job is to turn ideas into evidence that someone else can check. The distinction below guides everything we publish.

  • Generates hypotheses

    Reads the literature and points to possible disease mechanisms, therapeutic targets and questions that remain unanswered.

  • Produces evidence

    Analyzes data, tests models, attempts to reproduce published results and quantifies the uncertainty of each finding.

  • Does not replace the experiment

    A molecule suggested by AI is not a treatment. Efficacy and safety can only be shown in biological systems and, where authorized, in people.

Research lines

Four lines, one computational lab. We open the next one only when the previous one has reproducible results.

  • Computational biology

    Bioinformatics, genomics, therapeutic target discovery, proteins and simulations.

    Foundation for the other lines

  • Oncology

    Biomarkers, gene expression and mechanisms of treatment resistance.

    Pilot project being registered

  • Neuroscience and psychology

    Cognition, mental health, behavior and neuroimaging analysis.

    Future line

  • Immunology and vaccines

    Immune responses and computational assessment of vaccine candidates.

    Future line

Pilot project

Glioblastoma is an aggressive brain cancer that is well documented in public databases. It is a good first problem because other researchers can check every step we take.

Biomarkers of therapeutic resistance in glioblastoma

Question
Which gene expression patterns are associated with clinical outcome in glioblastoma, and do those associations hold in an independent dataset?
Data
TCGA-GBM, through the NCI Genomic Data Commons (open access). The second cohort, used for replication, is set in the project record.
Analysis
Association between expression and clinical outcome, controlling for confounders and correcting for multiple comparisons.
Deliverables
A tested Python pipeline, a technical report with limitations, and every result, including the negative ones.
Stage
Step 1 of 6: hypothesis being registered.

The first step is to reproduce a result that has already been published. Only then do we propose something new.

What this project is not

  • It is not a search for a cure in 90 days.
  • It is not evidence that a new treatment exists.
  • It does not use identifiable patient data.

How a question becomes a result

Five stages, always in the same order. Automation is partial: forming hypotheses, interpreting findings and publishing conclusions depend on a person’s decision.

  1. Literature investigation

    AI models search publications, compare evidence and flag gaps. Every reference is checked by DOI or PMID.

    Human decision: a person chooses the hypothesis

  2. Computational analysis

    Python and R pipelines run the analyses on public data, with automated tests and version control.

  3. Independent review

    A second model and a person check the statistics, biases, reproducibility and contrary evidence. Models can be wrong together, so AI review is never the last one.

    Human decision: a person interprets the findings

  4. Researcher assessment

    Specialists and partner institutions decide whether the finding justifies experimental validation.

  5. Publication

    Methods, code, limitations and verifiable results. AI use is disclosed and authorship always belongs to people.

    Human decision: a person signs off on the conclusions

Vemryx Research Engine

The internal platform we are building so that any result of ours can be redone by someone else. It is in development, starting with the pilot project’s pipeline.

  1. Data sources

    Papers, studies and public datasets, with origin, version and license on record.

  2. AI research

    Agents that read the literature and propose testable hypotheses.

    Requires human approval

  3. Experiment engine

    Analyses and simulations run in a controlled environment.

  4. Validation

    Statistical tests, replication and scientific review.

    Requires human approval

  5. Reproducibility

    Code, data and versions kept so each result can be redone.

  6. Publications

    Technical reports and manuscripts.

    Requires human approval

What every project keeps

It is what stops a platform like this from becoming a factory of bad papers.

  • The scientific question and hypothesis, written before the analysis.
  • The origin, version and license of each dataset.
  • The code and environment needed to reproduce the result.
  • Statistical tests, metrics and negative results.
  • Limitations and a specialist’s assessment.

Public data, licenses respected

We work with open, documented databases. When a database holds controlled-access data, we follow its licenses, restrictions and privacy rules.

For universities and research institutes

We bring engineering and method. We need people who know the biology better than we do.

We are developing a computational platform for reproducible analysis of biomedical data and biomarker identification. We are looking for scientific collaboration on methodological review, joint project development and, eventually, experimental validation.

What we offer

  • Software and AI engineering dedicated to the project.
  • Reproducible pipelines on public data.
  • Automated literature review, checked by a person.
  • Open code and auditable technical reports.

What we are looking for

  • Critical review of our methods.
  • Scientific guidance in biomedicine and bioinformatics.
  • Joint research and development projects.
  • Experimental validation when a finding justifies it.

We send a two-page technical summary covering the pilot project, the capabilities we already have and the ones we do not have yet.Request the technical summary

What we do alone and what we only do with partners

Health research has rules, and they exist for good reasons. This is the limit of what a software company should do on its own.

Types of research and how Vemryx Life Sciences takes part in each
Type of researchHow we take part
Literature review and analysisWe do it in-house.
Computational studies with public dataWe do it in-house, respecting licenses and access restrictions.
Development and evaluation of AI modelsWe do it in-house, with no unvalidated clinical use.
Experiments on cells and tissuesOnly in appropriate facilities, under the supervision of partner institutions.
Studies with human participantsOnly with prior ethics approval under the law of the country where the study takes place.
Clinical trials of drugs and vaccinesOnly with a sponsor, a qualified team and approval from the relevant regulators.
  • Sensitive data stays out of AI tools

    Identifiable medical data is not sent to models without a legal basis, a contract and security measures that meet the applicable data protection law.

  • AI is not an author

    We follow ICMJE guidance: AI use is disclosed in every manuscript and scientific responsibility lies with people.

  • A negative result is still a result

    We publish what was not confirmed with the same care as what was.

Read the evidence and AI use policy

The first 90 days

From 18 November 2026 to 16 February 2027. These are organizational goals, not promises of scientific results or signed partnerships.

  1. Days 1 to 15

    Scientific foundation

    • Choose one specific research problem
    • Create the repository and technical documentation
    • Adopt the evidence and AI use policy
  2. Days 16 to 30

    First experiment

    • Select a documented public dataset
    • Reproduce a published result
    • Build the pipeline with tests and versioning
  3. Days 31 to 60

    Validation and outreach

    • Seek validation in independent data
    • Write the technical report with its limitations
    • Present the proposal to research groups
  4. Days 61 to 90

    Partnerships and funding

    • Obtain a specialist’s assessment
    • Prepare a funding proposal, if viable
    • Define the next collaborative project

Does your group have a question that fits public data?

Tell us the question and what data exists. We reply with what we can do, how long it would take, and what we cannot do.

Writing about something else?